Low doses of the recombinant T-cell growth factor interleukin 2 (IL-2, aldesleukin, Proleukin) were well tolerated among patients with moderate-to-severe ulcerative colitis in a small 8-week study, with only one patient being withdrawn because of a dose-limiting toxicity, a researcher reported.
Scientific Publications
FDA ‘Fast Tracks’ Toripalimab in Frontline Mucosal Melanoma
The FDA granted a Fast Track designation (FTD) to the humanized PD-1 monoclonal antibody toripalimab for the first-line treatment of patients with mucosal melanoma, announced Junshi Biosciences, in a press release.1
Oncotarget: Improved therapeutic efficacy of unmodified anti-tumor antibodies
The cover for issue 2 of Oncotarget features Figure 4, “Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in “Improved therapeutic efficacy of unmodified anti-tumor antibodies….
OAM recipient dedicates honour to those lost to skin cancer
Melanoma Man’ Jay Allen has been recognised for his commitment to skin cancer awareness, today awarded a Medal of the Order of Australia.